Awakening guardian angels: drugging the p53 pathway

Brown, Christopher J., Lain, Sonia, Verma, Chandra S., Fersht, Alan R., Lane, David P.·2009·Nature Reviews Cancer
DOI 10.1038/nrc2763

Cited by (914)

Items 701–800 of 914

  1. De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia
    Amro Mohamed Sedky El-Ghammaz, Essam Abdelwahed, Nevine N. Mostafa, Dina A. Mansour · 2014 · Clinical and Experimental Medicine
  2. Pathophysiology of Cancer Cell Death
    Lorenzo Galluzzi, Andreas Linkermann, Oliver Kepp, Guido Kroemer · 2020 · Elsevier eBooks
  3. Hsa_circ_0080229 upregulates the expression of murine double minute-2 (MDM2) and promotes glioma tumorigenesis and invasion via the miR-1827 sponging mechanism
    Zhiwei Zhou, Xiuyuan Zheng, Xin Mei, Wengpeng Li, Songtao Qi, Yuefei Deng, Bingxi Lei · 2021 · Annals of Translational Medicine
  4. Molecular Biology and Anticancer Drug Discovery
    John Stephen Lazo · 2010 · Progress in molecular biology and translational science
  5. Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report
    Miron Prokocimer, SHOSHANA PELLER · 2011 · Medical Oncology
  6. Oxidative Stress and Carcinogenesis
    Mohinder Bansal, Naveen Kaushal · 2014 · Springer eBooks
  7. An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers
    Emilia Modolo Pinto, Raul Correa Ribeiro, Jiang Li, Lucía Taja‐Chayeb, Ligia Fu Carrasco, María de Lourdes Peña-Torres, Silvia Vidal-Millán, Hector Maldonado-Mtz, Alfonso Dueñas‐González, Lisa M. McGregor et al. · 2012 · Oncogenesis
  8. Lessons from the deep study of rare tumours
    David Morgan Thomas · 2011 · The Journal of Pathology
  9. A Dual-Specificity d -Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy
    Chongbing Liao, Jin Yan, William David Tolbert, Xishan Chen, Marzena Pazgier, Weiyue Lu, Changyou Zhan, Wuyuan Lu · 2025 · Journal of Medicinal Chemistry
  10. Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor
    Virginia Cristofori, Davide Illuminati, Chiara Bisquoli, Martina Catani, Greta Compagnin, Giulia Turrin, Claudio Trapella, Anna Fantinati · 2024 · Molecules
  11. CRISPR perfect adaptation for robust control of cellular immune and apoptotic responses
    Yichi Zhang, Shuyi Zhang · 2024 · Nucleic Acids Research
  12. A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment
    Sumel Ashique, Biplab Debnath, Mohhammad Ramzan, Tahreen Taj, Anas Islam, Priya Chaudhary, Monika Kaushik, Ashish Garg, Aniruddha Sen, Ciniraj Raveendran et al. · 2025 · Biomedicine & Pharmacotherapy
  13. Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: computational studies
    Yun Liu, David Philip Lane, Chandra Shekhar Verma · 2011 · Theoretical Chemistry Accounts
  14. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia
    Erhan Aptullahoğlu, Mohammed Howladar, Jonathan Peter Wallis, Helen J. Marr, Scott R Marshall, Julie A. E. Irving, Elaine Willmore, John Lunec · 2025 · Cancers
  15. Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
    Yiming Wen, Peijia Xu, Yijie Chen, Jingyi Meng, Mingyue Zheng, Sulin Zhang, Dan Teng, Xutong Li · 2025 · Molecular Diversity
  16. 1H, 13C and 15N backbone resonance assignment for the 40.5 kDa catalytic domain of Ubiquitin Specific Protease 7 (USP7)
    Paola Di Lello, Lionel Rougé, Borlan Pan, Till Maurer · 2016 · Biomolecular NMR Assignments
  17. Redefining the Protein–Protein Interface: Coarse Graining and Combinatorics for an Improved Understanding of Amino Acid Contributions to the Protein–Protein Binding Affinity
    Josh K. Smith, Shaoyi Jiang, Jim Pfaendtner · 2017 · Langmuir
  18. Dose and frequency in cancer therapy. Theoretical non-autonomous model of p53 network
    E. Silva, R. R. Martin, J. P. Pomuceno, Ricardo Mansilla, Juvencio Alberto Betancourt-Mar, G. Cocho, José Manuel Nieto-Villar · 2018 · Biological Rhythm Research
  19. Molecular Biology
    Daniel R. Clayburgh, Jennifer Rubin Grandis · 2017 · Elsevier eBooks
  20. Expression and purification of the recombinant full-length retinoblastoma protein and characterisation of its interaction with the oncoprotein HDM2
    Adriana Berenice Rousset-Roman, Yolanda Rebolloso‐Gómez, Vanesa Olivares‐Illana · 2019 · Protein Expression and Purification
  21. Cell Death and Cancer
    David Lawrence Vaux · 2013 · Springer eBooks
  22. Modelling and analysis of gene regulatory networks based on the G-network
    Haseong Kim · 2014 · International Journal of Advanced Intelligence Paradigms
  23. Gigantol: a principal bioactive constituent of Dendrobium species—multi-target mechanisms, network pharmacology, and therapeutic perspectives
    Sha Shi, Chengkai Zhu, Jiaqi Xu, Qi Sui, Shanhao Zhu, Jingnan Zhang, Peng Chen, Guang Liang, Yi Zhang · 2025 · Journal of Ethnopharmacology
  24. Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations
    Elham Gholizadeh, Ehsan Zangene, Alun Parsons, Mika Kontro, Caroline Akemi Heckman, Mohieddin Jafari · 2025 · Biomedicine & Pharmacotherapy
  25. Emerging Trends in Quinoxaline‐Based Analogs as Protein Kinase Inhibitors: Structural Developments and SAR Insights
    Shivani, Amol Tarachand Mahajan, Sandeep Chaudhary · 2024 · ChemMedChem
  26. Exploring 2,5-diphenyl furan derivative as promising inhibitor of p53-MDM2 interaction for cancer therapy
    Suvankar Karmakar, Biswajit Panda, Sourav Majumdar, Sk Eashayan Tanbir, Bula Singh, Samiran Mondal · 2025 · Next research.
  27. Regulation of PEST-containing nuclear proteins in cancer cells: implications for cancer biology and therapy
    Kaihong Jiang, Yong-Hao Zhu, Zhiwei Jiang, Yi Liu, Wahab Hussain, Huang-Yin Luo, Wei-Han Sun, Xin-Ying Ji, Dingxi Li · 2025 · Frontiers in Oncology
  28. Design and synthesis of multitarget triazinoindole derivatives with potent antiproliferative activity: Targeting EGFR, SIRT1, MDM2, Hsp90, PI3K, p53, and caspase-9
    Waleed A. Badawi, Eman S Ezz-ElDien, Mohamed A. El‐Atawy, Alaa Z. Omar, Ezzat Awad Hamed, Hoda A. Ahmed, Mariusz Jaremko, Abdul-Hamid M. Emwas, Tarek M. Okda, Mahmoud Zaki El-Readi et al. · 2025 · Bioorganic Chemistry
  29. The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling
    Milad J. Alasady, Alexander R. Terry, Adam D. Pierce, Michael C. Cavalier, Catherine S. Blaha, Kaylin A. Adipietro, Paul T. Wilder, David J. Weber, Nissim Hay · 2021 · PLoS ONE
  30. Interchain doubly-bridged α-helical peptides for the development of protein binders
    Yaqi Chen, Jingjing Liang, Tao Li, Ping J. Lin, Yibing Zhao, Chuanliu Wu · 2019 · Chinese Chemical Letters
  31. A Possible Link Between Autoimmunity and Cancer
    Erika Cristaldi, Giulia Malaguarnera, A Rando, Mariano Malaguarner · 2011 · InTech eBooks
  32. Activation of p53–p21 is closely associated with the acquisition of resistance to apoptosis caused by β1-integrin silencing in head and neck cancer cells
    Mi Ra Kim, Hyo Won Chang, Hae Yun Nam, Myung Woul Han, So Young Moon, Hyo Jung Kim, Hee Jin Lee, Jong‐Lyel Roh, Seong Who Kim, Sang Yoon Kim · 2012 · Biochemical and Biophysical Research Communications
  33. Zinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics
    Jenna M Guynn, Elizabeth Chan · 2017 · Molecular and integrative toxicology
  34. Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP
    Srividya, B H Giridhar, Shilpa Vishwanath, Anirban Chakraborty · 2018 · Pathology & Oncology Research
  35. Pathophysiology of Cancer Cell Death
    Lorenzo Galluzzi, Oliver Kepp, Guido Kroemer · 2014 · Elsevier eBooks
  36. Control of MicroRNA Maturation by p53 Tumor Suppressor and MCPIP1 Ribonuclease
    2012 · The Enzymes
  37. Planejamento de ligantes da tubulina com propriedades antitumorais
    Lívia de Barros Salum · 2011 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  38. p53/MDM2 Antagonists: Towards Nongenotoxic Anticancer Treatments
    Kareem Khoury, Tad A. Holak, Alexander S. S. Dömling · 2013 · Methods and principles in medicinal chemistry
  39. Drug discovery in the p53 field
    Sonia Laı́n · 2010 · Seminars in Cancer Biology
  40. Denaturation (Proteins)
    Alan Roy Fersht · 2013 · Elsevier eBooks
  41. TGx-DDI (toxicogenomic DNA damage-inducing) biomarker validation: multi-site ring trial supporting regulatory use
    Xiaotong Wang, Christine Crute, Ashley Allemang, Jiri Aubrecht, FLORENCE G. BURLESON, Yasmin Dietz, Lena Dorsheimer, Albert J. Fornace, Roland Frötschl, Ulrike Hemmann et al. · 2025 · Toxicological Sciences
  42. DNA Repair, Human Diseases and Aging
    Vaidehi Krishnan, Baohua Liu, Zhongjun Zhou · 2011 · InTech eBooks
  43. Cytotoxic activity of the leaf extract of Gardenia sokotensis (Hutch) against human colon cancer cells.
    Enzo Fornari, Pascal Nadembega, Luana Quassinti, Massimo Bramucci, K. H. Khalife, Ferruccio Poli, Hala-Gali Muhtasib, Giulio Lupidi · 2014 · Unicam Scientific Publications (University of Camerino)
  44. Cell Cycle, DNA Replication, Centrosomes, Centrioles and Cell Division
    Claudia Tanja Mierke · 2020 · Biological and medical physics, biomedical engineering
  45. E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies
    Zijian Zhou, Kaifeng Zheng, Shao Zhou, Youxiong Yang, Jun Chen, Xiaofeng Jin · 2023 · Journal of Molecular Medicine
  46. Structural Adaptation of Secondary P53 Binding Sites on Mdm2 and Mdmx
    Pirada S. Higbee, Guy W. Dayhoff, Asokan Anbanandam, Sameer Varma, Gary W. Daughdrill · 2024 · Journal of Molecular Biology
  47. VI-16, a newly synthesized flavonoid, induces apoptosis through the mitochondrial pathway in human hepatoma cells
    Qinglong Guo · 2011 · Oncology Reports
  48. TUMOR SUPPRESSOR PATHWAYS AND CELLULAR ORIGINS OF BREAST CANCER: NEW COMPLEXITIES AND NEW HOPES
    D. Joseph Jerry, Nicholas B. Griner, Luwei Tao · 2010 · Nano LIFE
  49. Natural compounds as a basis for the design of modulators of p53 activity
    Maxim Gureev, Pavel B. Davidovich, Vyacheslav G. Tribulovich, Alexander V. Garabadzhiu · 2014 · Russian Chemical Bulletin
  50. Genotoxicity of Nanomaterials in Food
    Venkatraman Manickam, Ranjith Kumar Velusamy, Rajeeva Lochana Panchangam, Amiti, Bhavapriya Rajendran, Ramasamy Tamizhselvi · 2017 · Sustainable agriculture reviews
  51. Disinfecting versus sanitizing. Selecting the right bleach makes all the difference when laundering hospital textiles.
    Nathan L. Belkin · 2003 · PubMed
  52. P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer
    Mohinder Pal Bansal · 2023 · Springer eBooks
  53. Republished: Sulphur alters NFκB-p300 cross-talk in favour of p53-p300 to induce apoptosis in non-small cell lung carcinoma
    Gaurisankar Sa, Tanya Das, Shilpi Saha, Bhattacharjee Pushpak, Deblina Guha, Kirti Kajal, Poulami Khan, Sreeparna Chakraborty, Shravanti Mukherjee, Shrutarshi Paul et al. · 2015 · Indian Journal of Research in Homoeopathy
  54. PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors
    Margarida Espadinha, Stuart J. Conway, Maria M. M. Santos · 2020 · Elsevier eBooks
  55. Evaluation of the anticancer potential of plants used as traditional medicines by Aboriginal people
    Donna L. Savigni · 2010 · UWA Profiles and Research Repository (University of Western Australia)
  56. Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists
    Arun Chandramohan, Hubert B. Josien, Tsz Ying Yuen, Ruchia Duggal, Diana Spiegelberg, Lin Yuan Yan, Yu-Chi Angela Juang, Lan Ge, Pietro G. A. Aronica, Kristal Kaan et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  57. Altered hormone expression induced genetic changes leads to breast cancer
    Anchal Thakur, Navya Rana, Ranjit Kumar · 2024 · Current Opinion in Oncology
  58. Multi-Step Synthesis of Chimeric Nutlin–DCA Compounds Targeting Dual Pathways for Treatment of Cancer
    Davide Illuminati, Rebecca Foschi, Paolo Marchetti, Vinicio Zanirato, Anna Fantinati, Claudio Trapella, Rebecca Voltan, Virginia Cristofori · 2025 · Molecules
  59. Molecular Drivers of Chromophobe Renal Cell Carcinoma Revealed Through Genomic Analysis Using AACR Project GENIE
    Abbi Gobel, Grace S. Saglimbeni, Eugene Manu, Nikhita Tandon, T C M Morris, Akaash Surendra, Beau Hsia, Peter T. Silberstein, Khalid Bashir, Abubakar Tauseef · 2025 · Life
  60. Targeting p53 Tumor Suppressor for AML Therapy
    Kensuke Kojima, Lyubomir T. Vassilev · 2014 · Springer eBooks
  61. Multivalent peptides displayed on OEGMA-based copolymers for the modulation of protein–protein interactions
    Yujie Li, Tao Li, Jinghui Wang, Xiaojia Bao, Yibing Zhao, Chuanliu Wu · 2015 · Polymer Chemistry
  62. Sénescence et immortalité cellulaire
    Chantal Trentesaux, Jean‐François Riou · 2010 · Bulletin du Cancer
  63. Back to Bases: How a Nucleotide Biosynthetic Enzyme Controls p53 Activation
    Anna L. Guarnieri, Joaquin Maximiliano Espinosa · 2014 · Molecular Cell
  64. Mapping Genes for Oligodendroglioma
    Chetan Bettegowda, Nickolas Papadopoulos, Nishant Agrawal · 2012 · Personalized Medicine
  65. Man of Science: Celebrating Professor Sir David Lane’s 60th anniversary
    Nikolai Zhelev · 2012 · Biodiscovery
  66. Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing
    Michael Bauer, Shweta S. Chavan, Erich Allen Peterson, Christoph Johann Heuck, Donald Joseph Johann · 2014 · BMC Bioinformatics
  67. Therapeutic implications for ovarian cancer emerging from the Tumor Cancer Genome Atlas
    Claire F. Verschraegen, Karen M. Lounsbury, Alan K. Howe, Marc S. Greenblatt · 2015 · Translational Cancer Research
  68. Thinking Inside the Box: Drosophila F-Box Protein Models of Human Disease
    Eric M. Merzetti, Colleen B. Connors, Brian E. Staveley · 2013
  69. Quantum-dot-based immunofluorescent imaging of Cancer Marker P53 Detection in Breast Cancer
    Wanying Xing, Qiang Li, Xing Ren, Guang Sun · 2016 · International Conference on Environment, Materials, Chemistry and Power Electronics (EMCPE)
  70. The facile and visualizable identification of broad-spectrum inhibitors of MDM2/p53 using co-expressed protein complexes
    Yang Yang, Zhiqiang Dong, Hongze Hu, Junhui Peng, Yaping Sheng, Tong Yang, Siming Yuan, Zigang Li, Jiaxiang Yang, Thomas Wells et al. · 2019 · The Analyst
  71. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability
    Yuan Tian, Brian R. Lahue, Yao Ma, Latha G. Nair, Weidong Pan, Ronald J. Doll, Timothy J. Guzi, Yao Ma, Yaolin Wang, Stephane L. Bogen · 2022 · Bioorganic & Medicinal Chemistry Letters
  72. Operation p53 Hunt to combat cancer Theaflavins in action
    Tanya Das · 2012 · Frontiers in Bioscience-Scholar
  73. Mucin‐producing urothelial‐type adenocarcinoma of the prostate with sarcomatoid features and novel molecular phenotype
    Pranav S. Renavikar, Thomas J Auen, David G. Wagner, Subodh M. Lele · 2023 · IJU Case Reports
  74. Tryptophanol-derived oxazoloisoindolinone fluorescent probes for cellular localization studies of p53 activators
    Hélio L. Barros, Margarida Espadinha, Sandra N. Pinto, Ricardo J. F. Ferreira, Joana B. Loureiro, Rita Silva, Lucı́lia Saraiva, Ermelinda Maçôas, Maria M. M. Santos · 2024 · Bioorganic Chemistry
  75. Unraveling the DNA Damage Response Signaling Network Through RNA Interference Screening
    Louise von Stechow, Bob van de Water, Erik H.J. Danen · 2014 · Elsevier eBooks
  76. P53 in Head and Neck Squamous Cell Carcinoma
    Janaki Parameswaran, Barbara Ann Burtness · 2018 · Current cancer research
  77. In Silico Design of MDM2‐Targeting Peptides from a Naturally Occurring Constrained Peptide
    He Ma, Peiju Qiu, Peta J. Harvey, Xiao Li, Zheyu Zhang, Qingliang Xu, Jiazhen Liang, Quentin Kaas, David J. Craik, Jinbo B. Yang et al. · 2019 · ChemMedChem
  78. In Vitro Analysis of Protein:Protein Interactions in the Human Cancer-Pertinent rp.eL42-p53-Mdm2 Pathway
    Blanche Aguida, Tahar Bouceba, Jean‐Bernard Créchet, Horrhus Hounguè, Callinice D. Capo‐chichi, Jun‐ichi Nakayama, Soria Baouz, Hélène Pelczar, Anne Woisard, Nathalie Jourdan et al. · 2019 · The Open Biochemistry Journal
  79. Biomimetic Synthesis of Rhytidenone A and Mode of Action of Cytotoxic Rhytidenone F
    Zongwei Yue, Hiu C. Lam, Kaiqi Chen, Ittipon Siridechakorn, Yaxi Liu, Khanitha Pudhom, Xiaoguang Lei · 2019 · Angewandte Chemie
  80. Computational investigation on the molecular interactions between MDM2 and its photoactivatable inhibitor
    2019 · Biointerface Research in Applied Chemistry
  81. Integrative Approaches to Cancer Care and Research through Yoga and Herbal Medicines during the Chemotherapy Treatment
    Rama Shankar, Rashmi Atul Joshi, Anupam Srivastava, Uday Bhan Prajapati · 2023 · Journal of Ayurveda and Integrated Medical Sciences
  82. An overview of Quinazolines: Applicability of molecular docking in Cancer therapy
    Manoj Kumar Yadav, Triloki Prasad, Rubal Rathi, Vivek Kumar Kushwaha, Vinay Kumar, Sachin Yadav, Deepak Kumar, Satyam Rai · 2023 · International Journal of Pharma Professional’s Research (IJPPR)
  83. Ground‐Breaking Changes in Mimetic and Novel Nanostructured Composites for Intelligent‐, Adaptive‐ and In vivo ‐Responsive Drug Delivery Therapies
    Dipak K. Sarker · 2012
  84. Regulation of the Tumor Suppresser p53 and Survivin by Ras and Ral GTPases:Implications for Malignant Transformation
    Awet Tecleab · 2013 · Digital Commons - University of South Florida (University of South Florida)
  85. Thioredoxin Reductase as a Target Enzyme for Electrophilic Anticancer Drugs
    Sofi E. Eriksson · 2011 · Figshare
  86. Nuevas aportaciones a la caracterización del cáncer de mama en mujeres jóvenes
    Athenea Pascual · 2017 · Gredos (University of Salamanca)
  87. FLIP(L) determines p53 induced life or death
    Andrea Lees, Alexander J. McIntyre, Fiammetta Falcone, Nyree Crawford, Christopher K. McCann, Gerard P. Quinn, Jamie Z. Roberts, Tamas Sessler, Peter F. Gallagher, Gemma Gregg et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  88. KRAS signalling in malignant pleural mesothelioma
    Antonia Marazioti, Christophe Blanquart, Anthi C. Krontira, Mario A. A. Pepe, Caroline M. Hackl, Marianthi P. Iliopoulou, Anne‐Sophie Lamort, Ina Koch, Michael Lindner, Rudolph Hatz et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  89. Upstream Targets in the p53 Pathway
    Anna R. McCarthy, Sonia Laı́n · 2012 · Springer eBooks
  90. The role of TRIM39 in cell cycle and apoptosis
    Nai-Jia Huang · 2013 · DukeSpace (Duke University)
  91. Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy
    Dale Han, Keiran S.M. Smalley · 2014 · Cancer drug discovery and develogment/Cancer drug discovery and development
  92. The role of 8q amplification and microRNAs in prostate cancer
    Sanni E. Jalava · 2012 · Tampere University Institutional Repository (Tampere University)
  93. TP53 mutations in myelodysplastic syndromes with deletion of 5q
    Leonie Saft · 2013 · Figshare
  94. DNA Repair, Cancer and Cancer Therapy
    Mu Wang · 2011 · InTech eBooks
  95. PHARMACOLOGICAL TARGETING OF P53 PATHWAY ALTERATIONS IN TUMORS
    Ying Zhao · 2010 · Figshare
  96. SNPing Away at Cancer
    Amanda M. Goh, David Philip Lane · 2010 · Cancer Cell
  97. The p53 homolog p63 modulates acute and chronic damage in irradiated salivary glands
    Geoffrey C. Mitchell · 2010 · UA Campus Repository (The University of Arizona)
  98. From peptides to proteins: lessons from my years at the Centre for Protein Engineering
    Assaf Friedler · 2010 · Protein Engineering Design and Selection
  99. Preclinical Pharmacology of the MDM2 Antagonist Nutlin-3a
    Fan Zhang · 2011
  100. Efficacy and Mechanism of Action of a Novel Class of Antic-Cancer Drugs
    Teran, Claudia · 2016 · uO Research (University of Ottawa)